This distinction is what sets diabetic cardiomyopathy apart from standard diabetic vascular risk factors and raises the specter of earlier hemodynamic primary preventative cardiac therapy even earlier than standard glycemic goals may dictate, especially in light of SGLT2 inhibitor effects. This evidence concerns the gene SLC5A2 and diabetic cardiomyopathy.